Publication | Closed Access
Recent advances in the chemistry of beta-lactam compounds as selected active-site serine beta-lactamase inhibitors.
20
Citations
0
References
1999
Year
Crystal StructurePharmacotherapyChemical BiologyPharmaceutical ChemistryB-lactam BondDrug ResistanceMolecular PharmacologyMedicinal ChemistryBeta-lactam CompoundsEnzyme ActionRecent AdvancesAntimicrobial ResistanceInhibitory ActivityBiochemistryAntibacterial AgentAntimicrobial CompoundDrug DevelopmentPharmacologyMolecular ModelingAntibioticsNatural SciencesMedicineDrug Discovery
The b-lactamases catalyze the hydrolysis of the b-lactam bond of a variety of b-lactam antibiotics destroying their antibacterial activity. During the last decades, there has been an inexorable spread of b-lactamase genes into species that previously were not known to possess them. One approach to combat the action of the b-lactamase is to inhibit the enzyme. However, inhibition of b-lactamase alone is not sufficient. The ability to penetrate the external membrane of Gram-negative bacteria, chemical stability, pharmacokinetics and other factors are also important in determining whether an inhibitor is suitable or not for therapeutic use. This review takes recent examples of synthetic b-lactam compounds developed as active-site serine b-lactamase inhibitors, emphasizing information on their structures and their activity against Ambler classes A, C and D b-lactamases. In addition, examples based on rational design by computerized molecular modeling of crystal structure of the native enzyme and mechanism of the enzyme action are highlighted.